AstraZeneca Plc has experienced a notable change in analyst sentiment due to a recent decrease in its stock price. UBS Group AG has upgraded the pharmaceutical company"s stock from a sell to a neutral rating, indicating the end of negative analyst coverage.

This upgrade coincides with a 1.3% increase in AstraZeneca"s shares on Wednesday. Currently, AstraZeneca has a positive outlook from analysts, with 24 buy ratings and seven hold ratings, and no sell or equivalent ratings. This shift in sentiment reflects growing confidence in the company"s performance despite recent market fluctuations.